BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...
Quarterly beat puts the spotlight on Attruby BridgeBio Pharma (BBIO) just delivered quarterly revenue that topped expectations, powered by stronger than anticipated U.S. sales of its cardiomyopathy ...
BridgeBio Pharma's fair value estimate has nudged higher to roughly $84.65 per share, as analysts bake in slightly stronger revenue growth assumptions of about 80.8% driven by better than expected ...
Fintel reports that on December 11, 2025, Wedbush reiterated coverage of BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) with a Outperform recommendation. Analyst Price Forecast Suggests 90.51% Upside ...
Fintel reports that on December 11, 2025, Bernstein initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Outperform ...
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing ...
A stark divergence is emerging around BridgeBio Pharma. On one side, prominent financial institutions are issuing ...
The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion ...
Wondering if BridgeBio Pharma is great value right now? You are not alone, especially with the biotech sector always buzzing and price tags swinging. The stock has been on a wild run, jumping 14.6% in ...
Summary • BridgeBio Oncology Therapeutics (BBOT) rises 17.7% in pre-market trading, reaching $14.49 from $12.31.• The ...
Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback